SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a full service Clinical Research Organization (CRO), announced today the continuation of its partnership with EndoCeutics, a bio-pharmaceutical company that has seven investigational products in its portfolio to treat women’s health issues, and to prevent and treat hormone-sensitive cancers. Veristat is currently preparing all of the outputs for an NDA submission for Prasterone (DHEA) to treat Dyspareunia or pain at sexual activity, a symptom of Vulvovaginal Atrophy due to menopause.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
